Pharmaceutical raw material testing plays an important role in ensuring that ingredients and manufacturing materials meet established identity, purity, and quality specifications before use in pharmaceutical production. Selecting the appropriate analytical testing approach depends on the material’s characteristics, intended application, and applicable regulatory or pharmacopeial requirements.
Compendial testing follows established analytical procedures and specifications outlined in recognized pharmacopoeias, such as the United States Pharmacopeia (USP–NF) and European Pharmacopoeia (Ph. Eur.). Non-compendial testing uses analytical methods not prescribed by an applicable pharmacopeial standard and may be necessary for specialized materials, complex formulations, or quality attributes not adequately addressed by existing compendial methods.
Depending on the material and its intended use, pharmaceutical manufacturers may require compendial testing, non-compendial testing, or a combination of both to appropriately evaluate raw material quality.
Understanding the differences between these testing approaches helps pharmaceutical and biotechnology manufacturers select suitable analytical methods, support supplier qualification, establish appropriate material specifications, and maintain consistent quality control throughout manufacturing.
BA Sciences provides comprehensive compendial and non-compendial pharmaceutical raw material testing services, including analytical method verification, development, and validation. Our experienced scientists work with clients to determine appropriate testing strategies based on material characteristics, project requirements, and applicable quality standards.
What Is Compendial Raw Material Testing?
Compendial raw material testing evaluates materials against applicable standards published in recognized pharmacopeias, including the United States Pharmacopeia–National Formulary (USP–NF), European Pharmacopoeia (Ph. Eur.), British Pharmacopoeia (BP), Japanese Pharmacopoeia (JP), and Chinese Pharmacopoeia (ChP). A monograph may establish identification procedures, assay requirements, impurity limits, or other quality attributes for a particular substance.
Testing requirements vary by material. Depending on the monograph and intended use, testing may include identity, assay or content, water determination, specified impurities, residual solvents, microbial quality, or physical properties. Biological activity is not a universal requirement for compendial materials. Likewise, elemental impurity testing is determined by applicable standards and risk assessment rather than automatically required for every incoming material.
Compendial status does not, by itself, establish that every supplier lot is suitable for a specific pharmaceutical process. Manufacturers must also consider material grade, supplier controls, intended use, and applicable written specifications.
What Is Non-Compendial Raw Material Testing?
Non-compendial raw material testing uses analytical procedures that are not prescribed by an applicable pharmacopeial standard. It may be appropriate when no monograph exists, when a material has unusual characteristics, or when additional quality attributes need evaluation beyond the applicable monograph.
Examples include certain proprietary formulation ingredients, novel excipients, specialized polymers, chromatography resins, and cell culture media components. The absence of a monograph does not mean a material is unsafe or exempt from quality requirements. Manufacturers still need scientifically justified specifications and suitable analytical procedures.
Non-compendial procedures may use established analytical technologies such as high-performance liquid chromatography (HPLC), gas chromatography (GC), Fourier transform infrared spectroscopy (FTIR), ultraviolet-visible spectroscopy (UV-Vis), or inductively coupled plasma mass spectrometry (ICP-MS).
What makes a procedure non-compendial is its status relative to an applicable pharmacopeial standard, not whether its instrumentation is novel.
Compendial vs. Non-Compendial Testing: Key Differences
| Consideration | Compendial Testing | Non-Compendial Testing |
|---|---|---|
| Procedure | Applicable pharmacopeial procedure | Procedure not prescribed by an applicable monograph |
| Specifications | Applicable monograph plus relevant product requirements | Scientifically justified material-specific criteria |
| Method suitability | Verification as appropriate under actual laboratory conditions | Qualification or validation appropriate to intended use |
| Applications | Materials with applicable pharmacopeial standards | Novel materials or additional analytical requirements |
| Documentation | Test records and verification evidence as applicable | Method development, suitability, and testing records as applicable |
The approaches are not mutually exclusive. A compendial ingredient may also undergo non-compendial testing to investigate a process-specific impurity, assess a critical material attribute, or meet additional product requirements.
Why Compendial Standards Matter for Pharmaceutical Quality Control
Pharmacopeial standards provide recognized procedures and acceptance criteria that support consistency in analytical testing. They help laboratories and manufacturers communicate material quality requirements and evaluate whether incoming components meet defined specifications. Compendial standards also support supplier qualification and documented material acceptance decisions.
However, requirements are not identical across all jurisdictions, and harmonization does not eliminate the need to review applicable local standards. Meeting a raw material monograph alone does not guarantee finished-product performance, which also depends on formulation, processing, stability, and other controls.
When Is Non-Compendial Raw Material Testing Necessary?
Non-compendial testing can address gaps between established standards and a manufacturer’s actual quality needs. It may be needed when a new excipient has no applicable monograph, when a proprietary ingredient requires characterization, or when a particular manufacturing process introduces attributes that a standard method does not measure.
The analytical plan should begin with the decision the data must support. For example, a laboratory might develop an identity procedure for a specialized polymer, establish a chromatographic impurity profile for a formulation component, or compare lot-to-lot variability across suppliers. In each case, acceptance criteria and method suitability should reflect the material, the intended use, and applicable regulatory expectations.
Extractables and leachables studies may also be relevant to pharmaceutical quality programs, but extractables and leachables are not themselves categories of raw materials. They are substances that may migrate from product-contact materials, equipment, or packaging and are assessed through related analytical studies.
What Does a Raw Material Testing Program Evaluate?
A well-designed pharmaceutical raw material testing program does more than produce a passing result. It connects each analytical measurement to a defined material specification and a documented quality decision. The tests selected should reflect the material’s composition, potential impurities, intended function, and risks associated with its use in manufacturing.
Identity testing helps establish that the received material is what the label and supplier documentation claim. Assay or content testing may quantify a specified component, while purity testing can evaluate relevant organic impurities, residual solvents, moisture, or elemental impurities. Microbiological testing may be appropriate for materials with particular contamination risks. Not every test is relevant to every material, and requirements should be selected using the applicable monograph, product knowledge, and risk assessment.
For example, a common solvent with an applicable pharmacopeial monograph may be evaluated using established identity and quality tests. A proprietary polymer used in a specialized formulation may require additional characterization of molecular properties or other performance-related attributes. In either case, specifications should be scientifically justified and the resulting data should be reviewed within the manufacturer’s quality system.
Method Verification vs. Method Validation
Method verification and method validation both establish confidence that an analytical procedure is suitable for its intended purpose, but they are not interchangeable.
USP General Chapter <1226> describes verification of compendial procedures when introduced into a laboratory.
Verification assesses selected performance characteristics under the actual conditions of use rather than repeating a complete validation. The extent of verification depends on the procedure, laboratory experience, and intended application; previously established procedures do not necessarily require repeat verification.
Method validation demonstrates that an analytical procedure performs adequately for its intended purpose. Relevant characteristics may include specificity, accuracy, precision, range, linearity, detection or quantitation limits, and robustness, depending on the test. Non-compendial procedures used for regulated decisions generally require appropriately documented suitability and, where applicable, validation. Not every exploratory procedure requires the same validation package.
How Supplier Qualification and Certificates of Analysis Fit In
A supplier Certificate of Analysis (CoA) can provide important evidence about a raw material lot, but it is not a substitute for an appropriate incoming-material control program. Manufacturers should determine which results they will confirm independently, how they will assess supplier reliability, and when additional testing is warranted. These decisions should reflect applicable regulations and the risk presented by the material.
Supplier qualification may consider manufacturing consistency, change-control practices, historical test results, deviations, and the ability to provide suitable documentation. Material specifications should also account for the grade purchased and its intended pharmaceutical use. A material meeting a supplier’s commercial specification does not automatically meet every requirement of a particular drug manufacturing process.
For laboratories, traceable sample identification, controlled analytical procedures, instrument qualification, appropriate reference materials, and complete data review support defensible results. When a method or specification changes, the organization should assess whether verification, validation, or additional comparability work is needed before relying on the updated procedure.
Regulatory Considerations for Raw Material Testing
In the United States, 21 CFR 211.84 addresses sampling, testing, and approval or rejection of components used in drug products. It requires at least one specific identity test for each component, with specific identity tests used when they exist. Components must also meet appropriate written specifications for purity, strength, and quality.
Under specified conditions, a manufacturer may accept a supplier report of analysis for certain attributes instead of repeating all testing, provided it performs the required identity testing and establishes the reliability of supplier analyses at appropriate intervals. A Certificate of Analysis does not automatically replace the manufacturer’s responsibilities.
Both compendial and non-compendial programs should address sampling, supplier qualification, traceability, documented procedures, suitable reference materials, data integrity, and quality review. Additional considerations may apply to biologically derived materials or materials with particular contamination risks; viral safety studies, for example, are not a blanket requirement for all non-compendial raw materials.
How to Choose the Appropriate Testing Approach
Begin by identifying the material’s grade, supplier, intended use, and applicable pharmacopeial monographs. Review whether existing procedures measure the quality attributes relevant to the manufacturing process. If a compendial procedure applies, determine whether laboratory verification is needed and whether additional product-specific tests are justified.
If no suitable procedure exists, define the analytical objective, select an appropriate technology, establish acceptance criteria, and determine the level of method development, qualification, or validation needed. The resulting testing strategy should be documented within the manufacturer’s quality system and reviewed against applicable regulatory requirements.
Common Challenges in Raw Material Testing
One challenge is variation between suppliers or between lots from the same supplier. Differences in moisture, particle characteristics, impurity profiles, or other attributes can affect manufacturing even when routine tests meet established limits. Additional analytical characterization may help a manufacturer understand whether an observed difference is meaningful for its process.
Another challenge arises when a compendial procedure is unsuitable for a particular sample matrix or cannot adequately measure an attribute of interest. The laboratory may need to investigate sample preparation, analytical interference, detection capability, or an alternative procedure. Any adaptation should be evaluated for its impact on method performance and on the validity of reported results.
Planning early can reduce avoidable delays. Before submitting samples, manufacturers should communicate the material identity, expected composition, relevant specifications, desired tests, available methods, and purpose of the data. Sharing prior analytical results and known material handling requirements can help the laboratory define a suitable scope of work without assuming that every material needs the same test panel.
Compendial and Non-Compendial Raw Material Testing
BA Sciences supports pharmaceutical raw material testing using compendial and non-compendial approaches. Our compendial experience includes major global pharmacopeias, and its laboratory maintains a database of previously verified raw material methods. Reviewing this verification history may help determine whether an existing procedure can be used without repeating verification activities, subject to the specific project and laboratory conditions.
BA Sciences also offers analytical techniques including FTIR, ICP-MS elemental analysis, UV-Vis spectroscopy, titration, and other wet chemistry and instrumental methods. For specialized testing requirements, its analytical development and validation capabilities can help establish procedures suitable for a defined material and quality objective.
Work With BA Sciences for Raw Material Testing
Accurate raw material testing is essential for pharmaceutical quality control, helping manufacturers verify material identity, purity, and compliance with applicable specifications. BA Sciences provides comprehensive compendial and non-compendial raw material testing services to support pharmaceutical and biopharmaceutical development and manufacturing.
With more than 30 years of experience, BA Sciences offers analytical testing capabilities that include chromatography, mass spectrometry, elemental impurity testing, particle-size analysis, and other methods used to evaluate pharmaceutical raw materials. Our team also provides compendial method verification, non-compendial method development and validation, and analytical testing to address specialized material requirements.
Our cGMP-compliant operations and established quality systems support reliable testing and documentation throughout pharmaceutical development and commercial manufacturing. Whether your organization needs to verify incoming raw materials, evaluate specialized ingredients, or establish appropriate analytical procedures, BA Sciences can help you meet your testing requirements.
Contact BA Sciences to discuss your compendial or non-compendial raw material testing needs and learn how our laboratory can support your pharmaceutical quality control program.